PMID- 35285011
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221011
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 37
IP  - 8
DP  - 2022 Aug
TI  - A comparative clinicopathological and survival analysis of synchronous bilateral 
      breast cancers.
PG  - 791-802
LID - 10.14670/HH-18-449 [doi]
AB  - OBJECTIVE: The present study aimed to explore the clinicopathological 
      characteristics, potential heterogeneity and prognostic factors in synchronous 
      bilateral breast cancer (SBBC). METHODS: We performed a retrospective review and 
      paired comparison of the clinicopathological characteristics of 114 patients with 
      SBBC in the Peking Union Medical College Hospital from January 2008 to September 
      2019. The prognostic significance of triple negativity status and coexistence 
      ductal carcinoma in situ (DCIS) with bilateral invasive ductal carcinomas of no 
      special type (IDC-NST) was analyzed in SBBC. RESULTS: Most bilateral lesions on 
      both sides were of IDC-NST, grade 2, luminal subtype, and stage I. Although most 
      lesions were concordant between the left and right side, discordances were 
      observed in histological type (25 cases, 21.9%), histological grade (31 cases, 
      27.2%), pTNM (61 cases, 53.5%), molecular subtypes (20 cases, 17.5%), and 
      immunohistochemical staining of ER (18 cases, 15.8%), PR (26 cases, 22.8%), and 
      HER2 (12 cases, 10.5%). Moreover, there was no significant difference in 
      disease-free survival (DFS) and overall survival (OS) between IDC-NST with 
      coexisting DCIS on both sides and IDC-NST with coexisting DCIS on one side or 
      pure IDC-NST. SBBC with triple negativity on both sides exhibited a significantly 
      shorter DFS and OS when compared with triple negativity on one side or non-triple 
      negativity on both sides (p<0.001), and remained an independent prognostic factor 
      by multivariate analysis. CONCLUSIONS: A considerable proportion of discordance 
      in clinicopathological characteristics is observed in SBBC, supporting the 
      necessity of comprehensive pathological examination including immunohistochemical 
      testing on both sides in clinical practice. Moreover, SBBC with triple negativity 
      on both sides is a prognostic for poor survival.
CI  - (c)The Author(s) 2022. Open Access. This article is licensed under a Creative 
      Commons CC-BY International License.
FAU - Bai, Yan
AU  - Bai Y
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Lu, Junliang
AU  - Lu J
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Wu, Huanwen
AU  - Wu H
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Niu, Yiru
AU  - Niu Y
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
AD  - Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
FAU - Pang, Junyi
AU  - Pang J
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Wu, Shafei
AU  - Wu S
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Liu, Yuanyuan
AU  - Liu Y
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China.
FAU - Liang, Zhiyong
AU  - Liang Z
AD  - Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, 
      Molecular Pathology Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      China. liangzhiyong1220@yahoo.com.
LA  - eng
GR  - 2016-I2M-1-002/CAMS Innovation Fund for Medical Sciences/
PT  - Journal Article
DEP - 20220314
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
SB  - IM
MH  - *Breast Neoplasms/pathology
MH  - *Carcinoma, Ductal, Breast/pathology
MH  - *Carcinoma, Intraductal, Noninfiltrating/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - Survival Analysis
EDAT- 2022/03/15 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/03/14 06:02
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/03/14 06:02 [entrez]
AID - HH-18-449 [pii]
AID - 10.14670/HH-18-449 [doi]
PST - ppublish
SO  - Histol Histopathol. 2022 Aug;37(8):791-802. doi: 10.14670/HH-18-449. Epub 2022 
      Mar 14.